Abstract
Antischizophrenic drugs exert their primary effects through blockade of dopamine (DA) receptors in the central nervous system (CNS)1–3. However, because of intricate interconnections between neural pathways, alteration of DA function in the CNS can lead to changes in the function of other neurotrans-mitters. In the basal ganglia, the turnover and utilisation of several neurotransmitters, including γ-aminobutyric acid (GABA)4–6, are indirectly influenced by nigrostriatal DA activity7–10. However, although attention has been focused on changes in DA receptors11,12, relatively little is known about changes in receptors for other transmitters after chronic anti-schizophrenic drug treatment. It is likely that changes occurring one or more synapses removed from the drugs' primary site of action may account for some of the time-dependent changes in the therapeutic and adverse clinical effects of antischizophrenic drugs13,14. In the substantia nigra (SN), a reduction in GABAergic inhibitory tone and a possible increase in the release of excitatory transmitter such as substance P are effects which seem to accompany the acute blockade of striatal DA receptors15. Recent studies have shown that a chronic decrease in GABA function in the SN, through the destruction of stria-tonigral pathways16,17, produces an increase in the number of GABA binding sites in the SN14,45. Therefore, if a relative deficit of GABA transmission in the SN were to be maintained by chronic antischizophrenic drug treatment, an increase in nigral GABA binding might occur. To investigate this possibility, two classical prototype antischizophrenic drugs (chlorpromazine and haloperidol) were examined for their effects on specific GABA binding in the SN and striatum of rats. These effects were compared with those of clozapine, an antischizophrenic drug with an atypical biochemical and clinical profile4,18–23. The data obtained, and reported here, support the hypothesis that chronic blockade of dopamine receptors by classical anti-schizophrenic drugs enhances GABA binding in the SN. This effect may be related to the extrapyramidal side effects associated with classical antischizophrenic drug treatment13.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anden, N. E., Butcher, S. G., Corrodi, H., Fuxe, K. & Ungerstedt, U. Eur. J. Pharmac. 11, 303–314 (1970).
Creese, I. & Snyder, S. H. in Psychopharmacology: A Generation of Progress (eds Lipton, M. A., DiMascio, A. & Killam, K. F.) 377–388 (Raven, New York, 1978).
Kebabian, J. W., Petzold, G. L. & Greengard, P. Proc. natn. Acad. Sci. U.S.A. 69, 2145–2149 (1972).
Mao, C. C., Cheney, D., Marco, E., Revuelta, A. & Costa, E. Brain Res. 132, 375–379 (1977).
Mao, C. C., Revuelta, A., Marco, E. & Costa, E. in Neuropsychopharmacology (eds Deniker, P., Radouco-Thomas, C. & Villeneuve, A.) 447–452 (Pergamon, Oxford, 1978).
Marco, E., Mao, C. C., Cheney, D. L., Revuelta, A. & Costa, E. Nature 264, 363–365 (1976).
Racagni, G., Cheney, D. L., Trabucchi, M. & Costa, E. J. Pharmac. exp. Ther. 196, 323–332 (1976).
Sethy, D. H. J. Neurochem. 27, 325–326 (1976).
Hong, J. S. et al. Brain Res. 160, 192–195 (1979).
Hong, J. S., Yang, H. Y. T. & Costa, E. Neuropharmacology 17, 83–85 (1978).
Burt, D. R., Creese, I. & Snyder, S. H. Science 196, 326–328 (1977).
List, S. J. & Seeman, P. Life Sci. 24, 1447–1452 (1979).
Baldessarini, R. J. & Tarsy, D. in Psychopharmacology: A Generation of Progress (eds Lipton, M. A., DiMascio, A. & Killam, K. F.) 993–104 (Raven, New York, 1978).
Davis, J. M. Am. J. Psychiat. 132, 1237–1245 (1975).
Gale, K., Costa, E., Toffano, G., Hong, J. S. & Guidotti, A. J. Pharmac. exp. Ther. 206, 29–37 (1978).
Waddington, J. L. & Cross, A. J. Nature 276, 618–620 (1978).
Guidotti, A., Gale, K., Suria, A. & Toffano, G. Brain Res. 172, 566–571 (1979).
Costall, B. & Naylor, R. J. Psychopharmacology 43, 69–74 (1975).
Gerlach, J., Koppelhus, P., Helweg, E. & Monrad, A. Acta psychiat. scand. 50, 410–424 (1974).
Hauser, D. & Closse, A. Life Sci. 23, 557–562 (1978).
Sayers, A. C., Burki, H. R., Ruch, W. & Asper, H. Psychopharmacology 41, 97–104 (1975).
Gale, K. in Long-Term Effects of Neuroleptics, Pharmacological Basis and Clinical Implications (eds Catabeni, F., Racagni, G., Spano, P. F. & Costa, E.) (Raven, New York, in the press).
Miller, R. J. & Hiley, C. R. Nature 248, 596–597 (1974).
Enna, S. J. & Snyder, S. H. Molec. Pharmac. 13, 442–453 (1977).
Toffano, G., Guidotti, A. & Costa, E. Proc. natn. Acad. Sci. U.S.A. 75, 4024–4028 (1978).
Gale, K. & Guidotti, A. Nature 263, 691–693 (1976).
Asper, H. et al. Eur. J. Pharmac. 22, 287–294 (1973).
Bowers, M. B. & Rozitis, A. J. Pharm. Pharmac. 26, 743–745 (1974).
Scatton, B. Eur. J. Pharmac. 46, 363–369 (1977).
Waldmeir, P. C. & Maitre, L. Eur. J. Pharmac. 38, 197–204 (1976).
Ribak, C. E., Vaughn, V. E., Saito, K., Barber, R. & Roberts, E. Brain Res. 116, 287–298 (1976).
Walters, J. & Lakoski, J. L. Eur. J. Pharmac. 47, 469–471 (1978).
Gale, K. Soc. Neurosci. Abstr. no. 231 (1979).
Oberlander, C., Dumont, C. & Boissier, J. R. Eur. J. Pharmac. 43, 389–390 (1976).
Koob, G. F., Del Fiacco, M. & Iversen, S. D. Adv. biochem. Psychopharmac. 16, 589–595 (1977).
Scheel-Kruger, J., Arnt, J. & Magelund, G. Neurosci. Lett. 4, 351–356 (1977).
Palfreyman, M. G., Huot, S., Lippert, B. & Schecter, P. J. Eur. J. Pharmac. 50, 325–336 (1978).
Matsui, Y. & Kamioka, T. Eur. J. Pharmac. 50, 243–251 (1978).
Klawans, H. L. & Rubovits, R. J. neural Transmission 33, 235–246 (1972).
Tarsy, D. & Baldessarini, R. J. Neuropharmacology 13, 927–940 (1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gale, K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283, 569–570 (1980). https://doi.org/10.1038/283569a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/283569a0
This article is cited by
-
Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose
Psychopharmacology (1995)
-
Autoradiographic localization of ?-aminobutyric acidA receptors within the ventral tegmental area
Neurochemical Research (1992)
-
Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats
Journal of Neural Transmission (1990)
-
Biochemical and behavioural properties of clozapine
Psychopharmacology (1989)
-
Effect of chronic haloperidol treatment on peripheral benzodiazepine binding sites in cerebral cortex of rats
Journal of Neural Transmission (1988)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.